The pharmaceutical community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s showing significant potential in clinical trials for managing obesity. Unlike some available weight loss solutions, retatrutide appears to offer a significant substantial loss